208 related articles for article (PubMed ID: 27521731)
41. [Complications of treatment of prolactinoma by dopamine agonists].
Astaf'eva LI; Kadashev BA; Kutin MA; Kalinin PL
Zh Vopr Neirokhir Im N N Burdenko; 2011; 75(2):41-50; discussion 50. PubMed ID: 21793295
[TBL] [Abstract][Full Text] [Related]
42. Visual vignette. Cabergoline therapy.
Stanciu I; Gordon DL
Endocr Pract; 2003; 9(5):475. PubMed ID: 14583429
[No Abstract] [Full Text] [Related]
43. 18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.
Heimburger C; Bund C; Addeo P; Goichot B; Imperiale A
Clin Nucl Med; 2018 Sep; 43(9):e324-e325. PubMed ID: 30052596
[TBL] [Abstract][Full Text] [Related]
44. Relapsed granulomatosis with polyangiitis with panhypopituitarism.
Triano MJ; Haberstroh WD; Lenka A; Whelton SA
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509867
[TBL] [Abstract][Full Text] [Related]
45. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
Brihaye B; Aouba A; Pagnoux C; Cohen P; Lacassin F; Guillevin L
Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S23-7. PubMed ID: 17428359
[TBL] [Abstract][Full Text] [Related]
46. Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline.
Dash S; Annamalai AK; Simpson HL; Sarkies N; Antoun NM; Mannion R
QJM; 2013 Jan; 106(1):85. PubMed ID: 22075008
[No Abstract] [Full Text] [Related]
47. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
48. An unusual association of a sellar gangliocytoma with a prolactinoma.
Serri O; Berthelet F; Bélair M; Vallette S; Asa SL
Pituitary; 2008; 11(1):85-7. PubMed ID: 17440820
[TBL] [Abstract][Full Text] [Related]
49. [Prolactin-secreting adenomas. Radiologic signs].
Metzger J; Bonneville JF; Bugault R
Acta Radiol Suppl; 1976; 347():327-38. PubMed ID: 207114
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic evaluation of hyperprolactinemia.
Biller BM
J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
[TBL] [Abstract][Full Text] [Related]
51. [Granulomatosis with polyangiitis (previously Wegener's granulomatosis) mimicking malingering].
Ene N; Bélénotti P; Benyamine A; Sovaila S; Ben Sahla Talet MH; Kaminsky P; Serratrice J; Weiller PJ
Rev Med Interne; 2014 Aug; 35(8):540-2. PubMed ID: 23886885
[TBL] [Abstract][Full Text] [Related]
52. Resolution of third nerve palsy following treatment of prolactinoma with cabergoline.
Harries AM; Gittoes NJ; Mitchell RD
Acta Neurochir (Wien); 2010 Oct; 152(10):1741-3. PubMed ID: 20623359
[TBL] [Abstract][Full Text] [Related]
53. Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review.
Gu Y; Sun X; Peng M; Zhang T; Shi J; Mao J
Rheumatol Int; 2019 Aug; 39(8):1467-1476. PubMed ID: 31203400
[TBL] [Abstract][Full Text] [Related]
54. Hypophysis Involvement in Granulomatosis With Polyangiitis.
Kocaer SB; Ozer E; Yilmaz E; Sari I
Arthritis Rheumatol; 2019 Jul; 71(7):1124. PubMed ID: 30816641
[No Abstract] [Full Text] [Related]
55. 68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma.
Basu S; Ranade R; Hazarika S
Clin Nucl Med; 2016 Mar; 41(3):230-1. PubMed ID: 26462040
[TBL] [Abstract][Full Text] [Related]
56. Prolactinomas may have unusual presentations resulting from massive extrasellar tumor extension.
Berriel MR; Lima GA; Melo AS; Santos ML; Rahhal H; Taboada GF
Arq Neuropsiquiatr; 2016 Jul; 74(7):544-8. PubMed ID: 27487374
[TBL] [Abstract][Full Text] [Related]
57. Misdiagnosis due to the hook effect in prolactin assay.
Yener S; Comlekci A; Arda N; Men S; Yesil S
Med Princ Pract; 2008; 17(5):429-31. PubMed ID: 18685288
[TBL] [Abstract][Full Text] [Related]
58. Pituitary dysfunction in granulomatosis with polyangiitis.
Esposito D; Trimpou P; Giugliano D; Dehlin M; Ragnarsson O
Pituitary; 2017 Oct; 20(5):594-601. PubMed ID: 28540625
[TBL] [Abstract][Full Text] [Related]
59. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
60. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
